[Captopril - profile of a new antihypertensive (author's transl)].
Captopril is a specific inhibitor of kininase II which is responsible for the conversion of angiotensin I into the active angiotensin II and also for the inactivation of bradykinin. In different types of experimental and clinical hypertension, Captopril has a pronounced blood pressure-reducing action particularly when it is given together with a diuretic. Serious side-effects have hitherto restricted the use of Captopril to patients who do not respond or do not respond satisfactorily to routine antihypertensives. Since it has been shown that a considerable improvement in disturbed hemodynamics in hypertension and in certain forms of heart failure can be achieved with quite low doses of the preparation (2 x 2 mg daily) the use of Captopril may be indicated in greater amounts in moderate and severe hypertension.
D000804:Angiotensin II / Q000097:blood; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D006978:Hypertension, Renovascular / Q000188:drug therapy; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains; D012083:Renin / Q000097:blood
D000959:Antihypertensive Agents; D000804:Angiotensin II; D011392:Proline; D002216:Captopril; D012083:Renin
[Captopril. Profil eines neuen Antihypertensivums.